Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Apr 15;101(8):1765–1774. doi: 10.1172/JCI167

Expression of the human histocompatibility leukocyte antigen DR3 transgene reduces the severity of demyelination in a murine model of multiple sclerosis.

K M Drescher 1, L T Nguyen 1, V Taneja 1, M J Coenen 1, J L Leibowitz 1, G Strauss 1, G J Hammerling 1, C S David 1, M Rodriguez 1
PMCID: PMC508759  PMID: 9541508

Abstract

The role of various MHC genes in determining the progression of multiple sclerosis (MS) remains controversial. The HLA-DR3 gene has been associated with benign relapsing MS in some genetic epidemiologic studies, but with disease progression in others. We induced demyelination in highly susceptible B10.M and B10.Q mice expressing the DR3 (HLA-DRB1*0301) transgene to determine directly the effects of a human transgene by infecting them with Theiler's murine encephalomyelitis virus (TMEV). DR3+ mice experienced a dramatic reduction in the extent and severity of demyelination compared with DR3- littermate controls, whereas anti-TMEV antibody titers, delayed-type hypersensitivity responses, and levels of infectious virus, virus antigen, and virus RNA were similar in both groups. To address a possible mechanism of how the human transgene is reducing virus-induced demyelination, we analyzed cytokine expression in the lesions and also determined whether B10.M mice can respond to peptides derived from the DR3 molecule. Intense staining for IFN-gamma and IL-4, T helper (TH) 1 and TH2 cytokines, respectively, was found in the lesions of TMEV-infected DR3- mice but not in the DR3+ transgenic mice at day 21 after infection. DR3 peptides elicited strong proliferative responses in B10.M mice but not in B10.M (DR3+) mice. These experiments are the first to demonstrate that a human class II DR gene can alter the severity of demyelination in an animal model of MS without influencing viral load. These experiments are consistent with a mechanism by which DR3 reduces demyelination by altering the cytokine expression in the lesions, possibly by deleting T cells involved in virus-induced pathology.

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black C., Briggs D., Welsh K. The immunogenetic background of scleroderma--an overview. Clin Exp Dermatol. 1992 Mar;17(2):73–78. doi: 10.1111/j.1365-2230.1992.tb00168.x. [DOI] [PubMed] [Google Scholar]
  2. Clatch R. J., Melvold R. W., Miller S. D., Lipton H. L. Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease in mice is influenced by the H-2D region: correlation with TEMV-specific delayed-type hypersensitivity. J Immunol. 1985 Aug;135(2):1408–1414. [PubMed] [Google Scholar]
  3. Duquette P., Décary F., Pleines J., Boivin D., Lamoureux G., Cosgrove J. B., Lapierre Y. Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression. Can J Neurol Sci. 1985 May;12(2):106–110. doi: 10.1017/s0317167100046795. [DOI] [PubMed] [Google Scholar]
  4. Ebers G. C., Kukay K., Bulman D. E., Sadovnick A. D., Rice G., Anderson C., Armstrong H., Cousin K., Bell R. B., Hader W. A full genome search in multiple sclerosis. Nat Genet. 1996 Aug;13(4):472–476. doi: 10.1038/ng0896-472. [DOI] [PubMed] [Google Scholar]
  5. Ebers G. C., Sadovnick A. D. Association studies in multiple sclerosis. J Neuroimmunol. 1994 Sep;53(2):117–122. doi: 10.1016/0165-5728(94)90021-3. [DOI] [PubMed] [Google Scholar]
  6. Engell T., Raun N. E., Thomsen M., Platz P. HLA and heterogeneity of multiple sclerosis. Neurology. 1982 Sep;32(9):1043–1046. doi: 10.1212/wnl.32.9.1043. [DOI] [PubMed] [Google Scholar]
  7. Fuks A., Ono S. J., Colle E., Guttmann R. D. A single dose of the MHC-linked susceptibility determinant associated with the RT1u haplotype is permissive for insulin-dependent diabetes mellitus in the BB rat. Exp Clin Immunogenet. 1990;7(3):162–169. [PubMed] [Google Scholar]
  8. Gerety S. J., Karpus W. J., Cubbon A. R., Goswami R. G., Rundell M. K., Peterson J. D., Miller S. D. Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus-induced demyelinating disease. V. Mapping of a dominant immunopathologic VP2 T cell epitope in susceptible SJL/J mice. J Immunol. 1994 Jan 15;152(2):908–918. [PubMed] [Google Scholar]
  9. Gerety S. J., Rundell M. K., Dal Canto M. C., Miller S. D. Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus-induced demyelinating disease. VI. Potentiation of demyelination with and characterization of an immunopathologic CD4+ T cell line specific for an immunodominant VP2 epitope. J Immunol. 1994 Jan 15;152(2):919–929. [PubMed] [Google Scholar]
  10. Jersild C., Svejgaard A., Fog T. HL-A antigens and multiple sclerosis. Lancet. 1972 Jun 3;1(7762):1240–1241. doi: 10.1016/s0140-6736(72)90962-2. [DOI] [PubMed] [Google Scholar]
  11. Kong Y. C., Lomo L. C., Motte R. W., Giraldo A. A., Baisch J., Strauss G., Hämmerling G. J., David C. S. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med. 1996 Sep 1;184(3):1167–1172. doi: 10.1084/jem.184.3.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Krco C. J., Beito T. G., David C. S. Determination of tolerance to self E alpha peptides by clonal elimination of H-2E reactive T cells and antigen presentation by H-2A molecules. Transplantation. 1992 Nov;54(5):920–923. doi: 10.1097/00007890-199211000-00029. [DOI] [PubMed] [Google Scholar]
  13. Lindsley M. D., Rodriguez M. Characterization of the inflammatory response in the central nervous system of mice susceptible or resistant to demyelination by Theiler's virus. J Immunol. 1989 Apr 15;142(8):2677–2682. [PubMed] [Google Scholar]
  14. Lipton H. L. Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect Immun. 1975 May;11(5):1147–1155. doi: 10.1128/iai.11.5.1147-1155.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Locksley R. M., Louis J. A. Immunology of leishmaniasis. Curr Opin Immunol. 1992 Aug;4(4):413–418. doi: 10.1016/s0952-7915(06)80032-4. [DOI] [PubMed] [Google Scholar]
  16. Miller D. J., Njenga M. K., Murray P. D., Leibowitz J., Rodriguez M. A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system inflammation and increases virus expression after Theiler's virus-induced demyelination. Int Immunol. 1996 Jan;8(1):131–141. doi: 10.1093/intimm/8.1.131. [DOI] [PubMed] [Google Scholar]
  17. Munk M. E., Emoto M. Functions of T-cell subsets and cytokines in mycobacterial infections. Eur Respir J Suppl. 1995 Sep;20:668s–675s. [PubMed] [Google Scholar]
  18. Mustonen J., Partanen J., Kanerva M., Pietilä K., Vapalahti O., Pasternack A., Vaheri A. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. Kidney Int. 1996 Jan;49(1):217–221. doi: 10.1038/ki.1996.29. [DOI] [PubMed] [Google Scholar]
  19. Njenga M. K., Pavelko K. D., Baisch J., Lin X., David C., Leibowitz J., Rodriguez M. Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice. J Virol. 1996 Mar;70(3):1729–1737. doi: 10.1128/jvi.70.3.1729-1737.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Patick A. K., Pease L. R., David C. S., Rodriguez M. Major histocompatibility complex-conferred resistance to Theiler's virus-induced demyelinating disease is inherited as a dominant trait in B10 congenic mice. J Virol. 1990 Nov;64(11):5570–5576. doi: 10.1128/jvi.64.11.5570-5576.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Paya C. V., Leibson P. J., Patick A. K., Rodriguez M. Inhibition of Theiler's virus-induced demyelination in vivo by tumor necrosis factor alpha. Int Immunol. 1990;2(9):909–913. doi: 10.1093/intimm/2.9.909. [DOI] [PubMed] [Google Scholar]
  22. Poser S., Ritter G., Bauer H. J., Grosse-Wilde H., Kuwert E. K., Raun N. E. HLA-antigens and the prognosis of multiple sclerosis. J Neurol. 1981;225(3):219–221. doi: 10.1007/BF00313751. [DOI] [PubMed] [Google Scholar]
  23. Pryhuber K. G., Murray K. J., Donnelly P., Passo M. H., Maksymowych W. P., Glass D. N., Giannini E. H., Colbert R. A. Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis. J Rheumatol. 1996 Apr;23(4):747–752. [PubMed] [Google Scholar]
  24. Pullen L. C., Miller S. D., Dal Canto M. C., Van der Meide P. H., Kim B. S. Alteration in the level of interferon-gamma results in acceleration of Theiler's virus-induced demyelinating disease. J Neuroimmunol. 1994 Dec;55(2):143–152. doi: 10.1016/0165-5728(94)90004-3. [DOI] [PubMed] [Google Scholar]
  25. Rodriguez M., David C. S. Demyelination induced by Theiler's virus: influence of the H-2 haplotype. J Immunol. 1985 Sep;135(3):2145–2148. [PubMed] [Google Scholar]
  26. Rodriguez M., Dunkel A. J., Thiemann R. L., Leibowitz J., Zijlstra M., Jaenisch R. Abrogation of resistance to Theiler's virus-induced demyelination in H-2b mice deficient in beta 2-microglobulin. J Immunol. 1993 Jul 1;151(1):266–276. [PubMed] [Google Scholar]
  27. Rodriguez M., Kenny J. J., Thiemann R. L., Woloschak G. E. Theiler's virus-induced demyelination in mice immunosuppressed with anti-IgM and in mice expressing the xid gene. Microb Pathog. 1990 Jan;8(1):23–35. doi: 10.1016/0882-4010(90)90005-b. [DOI] [PubMed] [Google Scholar]
  28. Rodriguez M., Lafuse W. P., Leibowitz J., David C. S. Partial suppression of Theiler's virus-induced demyelination in vivo by administration of monoclonal antibodies to immune-response gene products (Ia antigens). Neurology. 1986 Jul;36(7):964–970. doi: 10.1212/wnl.36.7.964. [DOI] [PubMed] [Google Scholar]
  29. Rodriguez M., Leibowitz J. L., Powell H. C., Lampert P. W. Neonatal infection with the Daniels strain of Theiler's murine encephalomyelitis virus. Lab Invest. 1983 Dec;49(6):672–679. [PubMed] [Google Scholar]
  30. Rodriguez M., Leibowitz J., David C. S. Susceptibility to Theiler's virus-induced demyelination. Mapping of the gene within the H-2D region. J Exp Med. 1986 Mar 1;163(3):620–631. doi: 10.1084/jem.163.3.620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rodriguez M., Nabozny G. H., Thiemann R. L., David C. S. Influence of deletion of T cell receptor V beta genes on the Theiler's virus model of multiple sclerosis. Autoimmunity. 1994;19(4):221–230. doi: 10.3109/08916939409071347. [DOI] [PubMed] [Google Scholar]
  32. Rodriguez M., Patick A. K., Pease L. R., David C. S. Role of T cell receptor V beta genes in Theiler's virus-induced demyelination of mice. J Immunol. 1992 Feb 1;148(3):921–927. [PubMed] [Google Scholar]
  33. Rodriguez M., Pavelko K. D., McKinney C. W., Leibowitz J. L. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol. 1994 Oct 15;153(8):3811–3821. [PubMed] [Google Scholar]
  34. Rodriguez M., Pierce M. L., Howie E. A. Immune response gene products (Ia antigens) on glial and endothelial cells in virus-induced demyelination. J Immunol. 1987 May 15;138(10):3438–3442. [PubMed] [Google Scholar]
  35. Rodriguez M., Sriram S. Successful therapy of Theiler's virus-induced demyelination (DA strain) with monoclonal anti-Lyt-2 antibody. J Immunol. 1988 May 1;140(9):2950–2955. [PubMed] [Google Scholar]
  36. Runmarker B., Martinsson T., Wahlström J., Andersen O. HLA and prognosis in multiple sclerosis. J Neurol. 1994 May;241(6):385–390. doi: 10.1007/BF02033356. [DOI] [PubMed] [Google Scholar]
  37. Sawcer S., Jones H. B., Feakes R., Gray J., Smaldon N., Chataway J., Robertson N., Clayton D., Goodfellow P. N., Compston A. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet. 1996 Aug;13(4):464–468. doi: 10.1038/ng0896-464. [DOI] [PubMed] [Google Scholar]
  38. Sher A., Gazzinelli R. T., Oswald I. P., Clerici M., Kullberg M., Pearce E. J., Berzofsky J. A., Mosmann T. R., James S. L., Morse H. C., 3rd Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev. 1992 Jun;127:183–204. doi: 10.1111/j.1600-065x.1992.tb01414.x. [DOI] [PubMed] [Google Scholar]
  39. Stenszky V., Kozma L., Balazś C., Bear J. C., Farid N. R. The role of HLA antigens in the manifestation and course of Graves' disease. Mol Biol Med. 1986 Feb;3(1):53–62. [PubMed] [Google Scholar]
  40. Strauss G., Vignali D. A., Schönrich G., Hämmerling G. J. Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice. Immunogenetics. 1994;40(2):104–108. [PubMed] [Google Scholar]
  41. Welsh C. J., Tonks P., Nash A. A., Blakemore W. F. The effect of L3T4 T cell depletion on the pathogenesis of Theiler's murine encephalomyelitis virus infection in CBA mice. J Gen Virol. 1987 Jun;68(Pt 6):1659–1667. doi: 10.1099/0022-1317-68-6-1659. [DOI] [PubMed] [Google Scholar]
  42. Wolfgram L. J., Beisel K. W., Herskowitz A., Rose N. R. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J Immunol. 1986 Mar 1;136(5):1846–1852. [PubMed] [Google Scholar]
  43. Zanelli E., Gonzalez-Gay M. A., David C. S. Could HLA-DRB1 be the protective locus in rheumatoid arthritis? Immunol Today. 1995 Jun;16(6):274–278. doi: 10.1016/0167-5699(95)80181-2. [DOI] [PubMed] [Google Scholar]
  44. Zanelli E., Krco C. J., Baisch J. M., Cheng S., David C. S. Immune response of HLA-DQ8 transgenic mice to peptides from the third hypervariable region of HLA-DRB1 correlates with predisposition to rheumatoid arthritis. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1814–1819. doi: 10.1073/pnas.93.5.1814. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES